Salix Pharmaceuticals has acquired the worldwide intellectual property rights relating to Olon’s amorphous rifaximin.
A pending patent application covering amorphous rifaximin, an issued patent covering the product along with related intellectual property rights that was acquired by Olon from Apotex Pharmachem were purchased by Salix.
Indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age and more, Xifaxan 550mg is a rifamycin antibacterial.
Based in North Carolina, Salix Pharmaceuticals develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/salix-acquires-worldwide-intellectual-property-rights-to-olons-amorphous-rifaximin-300513
